Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B Prometheus deal.
Merck’s $10.8 billion buyout of Prometheus Biosciences is showing its first signs of paying off.
The lead program of that acquisition succeeded in its first …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy - Merck & Co (NYSE:MRK)
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart - Merck
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth…
